Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

DOI: 10.1186/s12933-019-0871-8

Keywords: Semaglutide, Cardiovascular events, Gender, Age, Baseline cardiovascular risk, Type 2 diabetes, SUSTAIN 6, Cardiovascular outcome trial

Full-Text   Cite this paper   Add to My Lib

Abstract:

The online version of this article (10.1186/s12933-019-0871-8) contains supplementary material, which is available to authorized users

Full-Text